David Sinclair (Life Biosciences) OSK Human Trials Is Now Live. We Will See OSK Being Injected Into Humans in 2026

Key Takeaways

• Life Biosciences received FDA IND clearance for OSK therapy ER‑100.
• Human trials target age‑related glaucoma, starting 2026 with AAV delivery.
• Preclinical studies showed OSK extends mouse lifespan by ~10% and restores vision.
• Safety concerns include dedifferentiation risk, tumor formation, and dosing challenges.
• Success could launch a new market for gene‑therapy anti‑aging treatments.

Pulse Analysis

David Sinclair’s Life Biosciences has moved epigenetic reprogramming from the lab toward clinical reality. The company builds on the information‑theory of aging, which treats age‑related decline as a loss of epigenetic “software” rather than irreversible DNA damage. By harnessing the OSK transcription factors—Oct4, Sox2 and Klf4—researchers can partially reset cellular age without triggering full pluripotency. Recent AI‑driven screens of billions of virtual compounds have identified small‑molecule mimetics, but the most advanced approach remains viral delivery of the OSK genes themselves.

In January 2026 the U.S. Food and Drug Administration granted an Investigational New Drug (IND) clearance for Life Biosciences’ ER‑100, an AAV‑based OSK therapy aimed at age‑related glaucoma. The first human participant is slated to receive intravitreal injections in early 2026, marking the first regulated administration of an epigenetic reprogramming cocktail in people. Preclinical data show a roughly 10 % increase in mouse lifespan and full restoration of retinal function, yet the platform carries known risks such as cellular dedifferentiation, tumorigenesis, and precise dose‑control challenges.

If the trial demonstrates safety and measurable visual improvement, OSK could catalyze a new segment of gene‑therapy anti‑aging products. Investors are watching for a potential shift from niche, $100k‑plus cell therapies to scalable treatments that address multiple age‑related conditions. However, regulatory scrutiny will remain intense, given the historical concern over teratoma formation and off‑target effects. Successful navigation of these hurdles would not only validate Sinclair’s epigenetic theory but also accelerate the broader longevity industry toward mainstream medical adoption.